<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FOSPHENYTOIN SODIUM</span><br/>(fos-phen'i-toin)<br/><span class="topboxtradename">Cerebyx<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">hydantoin anticonvulsant agent</span><br/><b>Prototype: </b>Phenytoin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 750 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Prodrug of phenytoin that converts to the anticonvulsant, phenytoin, after parenteral administration. Thought to modulate
         the sodium channels of neurons, calcium flux across neuronal membranes, and enhance the sodiumpotassium ATPase activity
         of neurons and glial cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The cellular mechanism of phenytoin is thought to be responsible for the anticonvulsant activity of fosphenytoin.</p>
<h1><a name="uses">Uses</a></h1>
<p>Control of generalized convulsive status epilepticus and the prevention and treatment of seizures during neurosurgery, or
         as a parenteral short-term substitute for oral phenytoin.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Antiarrhythmic agent especially in treatment of digitalis-induced arrhythmia; treatment of trigeminal neuralgia (tic douloureux).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to hydantoin products, rash, seizures due to hypoglycemia, sinus bradycardia, complete or incomplete heart
         block; AdamsStokes syndrome; pregnancy (category D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired liver or kidney function, alcoholism, hypotension, heart block, bradycardia, severe CAD, diabetes mellitus, hyperglycemia,
         respiratory depression, acute intermittent porphyria.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Status Epilepticus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 1520 mg PE/kg (PE = phenytoin sodium equivalents) administered at 100150 mg PE/min <span class="rdroute">IV Maintenance Dose</span> is 46 mg PE/kg/d<br/><br/><span class="indicationtitle">Substitution for Oral Phenytoin Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> Substitute fosphenytoin at the same total daily dose in mg PE as the oral dose at a rate of infusion not greater than 150
               mg PE/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: All dosing is expressed in phenytoin sodium equivalents (PE) to avoid the need to calculate molecular weight adjustments between
            fosphenytoin and phenytoin sodium doses. <b>
<small>ALWAYS</small>
</b> prescribe and fill fosphenytoin in PE units.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Follow institutional policy regarding maximum volume to inject into one IM site.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute in DSW or NS to a concentration of 1.525 mg PE/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Do not administer at a rate &gt;150 mg PE/min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 2°8° C (36°46° F); may store at room temperature not to exceed 48 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Usually dose related. Paresthesia, tinnitus, <span class="speceff-common">nystagmus, dizziness, somnolence, drowsiness,</span> ataxia, mental confusion, tremors, insomnia, headache, seizures, increased reflexes, dysarthria, intracranial hypertension. <span class="typehead">CV:</span> Bradycardia, tachycardia, asystole, hypotension, hypertension, <span class="speceff-life">cardiovascular collapse, cardiac arrest</span>, heart block, ventricular fibrillation, phlebitis. <span class="typehead">Special Senses:</span> Photophobia, conjunctivitis, diplopia, blurred vision. <span class="typehead">GI:</span>
<span class="speceff-common">Gingival hyperplasia,</span> nausea, vomiting, constipation, epigastric pain, dysphagia, loss of taste, weight loss, hepatitis, liver necrosis. <span class="typehead">Hematologic:</span> Thrombocytopenia, leukopenia, leukocytosis, <span class="speceff-life">agranulocytosis</span>, pancytopenia, eosinophilia; megaloblastic, hemolytic, or <span class="speceff-life">aplastic anemias</span>. <span class="typehead">Metabolic:</span> Fever, hyperglycemia, glycosuria, weight gain, edema, transient increase in serum thyrotropic (TSH) level, hyperkalemia, osteomalacia
      or rickets associated with hypocalcemia and elevated alkaline phosphatase activity. <span class="typehead">Skin:</span> Alopecia, hirsutism (especially in young female); rash: scarlatiniform, maculopapular, urticarial, morbilliform (may be fatal);
      bullous, exfoliative, or purpuric dermatitis; StevensJohnson syndrome, <span class="speceff-life">toxic epidermal necrolysis</span>, keratosis, neonatal hemorrhage, <span class="speceff-common">pruritus.</span>
<span class="typehead">Urogenital:</span> Acute renal failure, Peyronie's disease. <span class="typehead">Respiratory:</span> Acute pneumonitis, pulmonary fibrosis. <span class="typehead">Musculoskeletal:</span> Periarteritis nodosum, acute systemic lupus erythematosus, craniofacial abnormalities (with enlargement of lips). <span class="typehead">Other:</span> Lymphadenopathy, injection site pain, chills. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Fosphenytoin may produce lower than normal values for <span class="alt">dexamethasone</span> or <span class="alt">metyrapone</span> tests; may increase serum levels of <span class="alt">glucose,</span>
<span class="alt">BSP,</span> and <span class="alt">alkaline phosphatase</span> and may decrease <span class="alt">PBI</span> and <span class="alt">urinary steroid</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> decreases fosphenytoin effects; <span class="classification">other anticonvulsants</span> may increase or decrease fosphenytoin levels; fosphenytoin may decrease absorption and increase metabolism of <span class="classification">oral anticoagulants</span>; fosphenytoin increases metabolism of <span class="classification">corticosteroids</span> and <span class="classification">oral contraceptives</span>, thus decreasing their effectiveness; <b>amiodarone,</b>
<b>chloramphenicol,</b>
<b>omeprazole</b> increase fosphenytoin levels; <span class="classification">antituberculosis agents</span> decrease fosphenytoin levels. <span class="typehead">Food:</span>
<b>Folic acid,</b>
<b>calcium,</b>
<b>vitamin D</b> absorption may be decreased by fosphenytoin; fosphenytoin absorption may be decreased by enteral nutrition supplements. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed after IM administration. <span class="typehead">Peak:</span> 30 min IM. <span class="typehead">Distribution:</span> 9599% bound to plasma proteins, displaces phenytoin from protein binding sites; crosses placenta, small amount in
      breast milk. <span class="typehead">Metabolism:</span> Converted to phenytoin by phosphatases; phenytoin is oxidized in liver to inactive metabolites. <span class="typehead">Elimination:</span> Half-life 15 min to convert fosphenytoin to phenytoin, 22 h phenytoin; phenytoin metabolites excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p>
         				Note: See <b>phenytoin</b> for additional nursing implications.
         			
      </p>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG, BP, and respiratory function continuously during and for 1020 min after infusion.</li>
<li>Discontinue infusion and notify physician if rash appears. Be prepared to substite alternative therapy rapidly to prevent
            withdrawal-precipitated seizures.
         </li>
<li>Lab tests: Monitor CBC with differential, platelet count, serum electrolytes, and blood glucose.</li>
<li>Allow at least 2 h after IV infusion and 4 h after IM injection before monitoring total plasma phenytoin concentration.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Monitor carefully for adverse effects, especially in patients with renal or hepatic disease or hypoalbuminemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of potential adverse effects. Itching, burning, tingling, or paresthesia are common during and for some time following
            IV infusion.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>